Cargando…
Relapsed Myasthenia Gravis after Nivolumab Treatment
Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although “new-onset” autoimmune diseases are well-known immune-related adverse events, whether or not nivoluma...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Japanese Society of Internal Medicine
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064691/ https://www.ncbi.nlm.nih.gov/pubmed/29434145 http://dx.doi.org/10.2169/internalmedicine.9153-17 |